SELLAS Life Sciences Group AI Stock Analysis
SELLAS Life Sciences Group (RXK3) AI Stock Analysis
SELLAS Life Sciences Group
(XETRA:RXK3)
No summary available
SELLAS Life Sciences Group (RXK3) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 2.78B
- Dividend Yield
- ―
- Average Volume (3M)
- 1,444
- Price to Earnings (P/E)
- -68.7
- Beta (1Y)
- -0.46
- Revenue Growth
- ―
- EPS Growth
- 34.25%
- Country
- Germany
- Employees
- 13
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
SELLAS Life Sciences Group Business Overview & Revenue Model
Company Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a p...
SELLAS Life Sciences Group Risk Analysis
SELLAS Life Sciences Group disclosed 77 risk factors in its most recent earnings report. SELLAS Life Sciences Group reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksSELLAS Life Sciences Group Peers Comparison
Overall Rating
XNCR61Neutral
ARVN60Neutral
IOVA56Neutral
ORIC48Neutral
NBTX41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | $2.55B | -21.18 | -21.29% | ― | 33.55% | 11.51% | |
| 60Neutral | $441.37M | -43.07 | -2.00% | ― | -11.85% | 81.44% | |
| 56Neutral | $3.38B | -13.02 | -29.71% | ― | 51.31% | 56.78% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $800.27M | -5.04 | -40.99% | ― | ― | 15.37% | |
| 41Neutral | $1.45B | -22.13 | 89.71% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:RXK3 | Sellas Life Sciences Group | 12.55 | 11.20 | 832.39% | |
| XNCR | Xencor Inc. | 33.26 | 16.52 | 98.69% | |
| IOVA | Iovance Biotherapeutics | 6.90 | 4.40 | 176.00% | |
| ARVN | Arvinas Holding Company | 6.46 | -5.31 | -45.11% | |
| ORIC | Oric Pharmaceuticals Inc | 7.36 | -4.43 | -37.57% | |
| NBTX | Nanobiotix Sa ADR | 26.50 | 4.50 | 20.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
